ISSN 2415-3060 (print), ISSN 2522-4972 (online)
  • 8 of 67
УЖМБС 2020, 5(3): 68–73
Medicine. Reviews

Markers of systemic inflammation in COPD patients with obesity

Kuznetsova L.1, Gopko О. 2, Savchenko L.2

Chronic obstructive pulmonary disease is one of the most common respiratory diseases in which comorbid pathology is detected in almost 90% of patients. Particular attention in the clinic of internal medicine deserves a coexisting with alimentary obesity due to the following risk factors: population aging, hypodynamia, over-nutrition, which contributes to the progression of comorbid pathology and the development of complications. The chronic inflammatory process is the main link in the pathogenesis of chronic obstructive pulmonary disease, which causes structural changes of the respiratory tract and lungs (bronchial obstruction and loss elasticity of the lung parenchyma) against the background of systemic inflammation, especially in overweight patients. So, the purpose of the work was to analyze literature data on the common markers of systemic inflammation in chronic obstructive pulmonary disease patients with obesity. High sensitivity C-reactive protein is an acute-phase protein synthesized mainly by hepatocytes in response to the bronchopulmonary tissue damage by the inflammatory process. The research has demonstrated the relationship between the high sensitivity C-reactive protein and functional ventilatory capacity, clinical chronic obstructive pulmonary disease severity. Adipose tissue is considered as an endocrine organ and a source of biologically active substances: adipokines, bioactive peptides, free fatty acids, monocytic chemotactic factor-1 (monocyte chemotactic protein-1), pro-inflammatory cytokines, involved in systemic inflammation in many pathological conditions, including respiratory diseases. There are many works focused on the study of leptin as a pleiotropic hormone determining the state of immune homeostasis and angiogenesis. However, a remarkable discovery was the determination of the leptin role in the respiratory tract. Leptin is a stimulator of ventilation, a factor determining the processes of maturation and development of the lungs, as well as respiratory diseases, including obstructive sleep apnea syndrome, bronchial asthma, chronic obstructive pulmonary disease and lung cancer. It should be noted that leptin is involved in airway inflammation in chronic obstructive pulmonary disease, possibly due to the regulation of infiltration and apoptosis of immune cells in the submucosal basis of the bronchi. Conclusion. Thus, obesity has a significant effect on the intensity of systemic inflammation in patients with chronic obstructive pulmonary disease. High sensitivity C-reactive protein and leptin are the common biomarkers of systemic inflammation that can be used to assess the severity of chronic obstructive pulmonary disease and obesity.

Keywords: chronic obstructive pulmonary disease, obesity, high sensitivity C-reactive protein, leptin

Full text: PDF (Ua) 153K

  1. Samuleeva YuV, Zadyonchenko VS, Ly VV, Adasheva TV, Samorukova EY, Pykhlak AE, et al. Ozhirenie i metabolicheskie narusheniya u bolnykh khronicheskoy obstruktivnoy boleznyu legkikh: vozmozhnosti fenotipirovaniya. Pulmonologiya. 2014; (5): 32-8. [Russian]
  2. Barnes PJ. Cellular and molecular mechanisms of chronic obstructive pulmonary disease. Clin Chest Med. 2014; 35(1): 71-86.
  3. Vanfleteren LE, Spruit MA, Groenen M, Gaffron S, van Empel VP, Bruijnzeel PL, et al. Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013; 187(7): 728-35.
  4. Barnes PJ. Inflammatory mechanisms in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2016; 138(1): 16-27.
  5. Forsslund H, Yang M, Mikko M, Karimi R, Nyrén S, Engvall B, et al. Gender differences in the T-cell profiles of the airways in COPD patients associated with clinical phenotypes. Int J Chron Obstruct Pulmon Dis. 2016; 12: 35-48.
  6. Halper-Stromberg E, Yun JH, Parker MM, Singer RT, Gaggar A, Silverman EK, et al. Systemic Markers of Adaptive and Innate Immunity Are Associated with Chronic Obstructive Pulmonary Disease Severity and Spirometric Disease Progression. Am J Respir Cell Mol Biol. 2018; 58(4): 500-9.
  7. Brekke PH, Omland T, Holmedal SH. Troponin-T elevation and long-term mortality after chronic obstructive pulmonary disease exacerbation. EurRespir J. 2008; 31: 563-70.
  8. He JQ, Foreman MG, Shumansky K. Associations of IL-6 polymorphisms with lung function decline and COPD. Thorax. 2009; 64: 698-704.
  9. Inoue Y, Kawayama T, Iwanaga T. High plasma brain natriuretic peptide levels in stable COPD without pulmonary hypertension or Corpulmonale. Intern Med. 2009; 48: 503-12.
  10. Papaioannou AI, Mazioti A, Kiropoulos T, Tsilioni I, Koutsokera A, Tanou K, et al. Systemic and airway inflammation and the presence of emphysema in patients with COPD. Respir Med. 2010; 104(2): 275-82.
  11. Pinto-Plata VM, Müllerova H, Toso JF, Feudjo-Tepie M, Soriano JB, Vessey RS, et al. C-reactive protein in patients with COPD, control smokers and non-smokers. Thorax. 2006; 61(1): 23-8.
  12. Comes A, Ianoși ES, Jimborean G. Inflammatory Biomarkers in Chronic Obstructive Pulmonary Disease. Journal of Interdisciplinary Medicine. 2016; 1(1): 12-7.
  13. de Torres JP, Pinto-Plata V, Casanova C, Mullerova H, Córdoba-Lanús E, de Fuentes MM, et al. C-reactive protein levels and survival in patients with moderate to very severe COPD. Chest. 2008; 133(6): 1336-43.
  14. Alavi SA, Soati F, Forghanparast K, Amani H. HsCRP in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease. Iran Red Crescent Med J. 2011; 13(10): 713-8.
  15. Deng ZC, Zhao P, Cao C, Sun SF, Zhao F, Lu CY, et al. C-reactive protein as a prognostic marker in chronic obstructive pulmonary disease. Exp Ther Med. 2014; 7(2): 443-6.
  16. Leuzzi G, Galeone C, Taverna F, Suatoni P, Morelli D, Pastorino U. C-reactive protein level predicts mortality in COPD: a systematic review and meta-analysis. Eur Respir Rev. 2017; 26(143): 160-70.
  17. Koul PA. Metabolic syndrome and chronic obstructive pulmonary disease. Lung India. 2016; 33: 359-61.
  18. Agustí A, Edwards LD, Rennard SI, MacNee W, Tal-Singer R, Miller BE, et al. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS One. 2012; 7(5): e37483.
  19. Agarwal R, Zaheer MS, Ahmad Z, Akhtar J. The relationship between C-reactive protein and prognostic factors in chronic obstructive pulmonary disease. Multidiscip. Respir. Med. 2013; 8 (1): 63.
  20. Savchenko L, Mykytiuk M, Cinato M, Tronchere H, Kunduzova O, Kaidashev I. IL-26 in the induced sputum is associated with the level of systemic inflammation, lung functions and body weight in COPD patients. Int J Chron Obstruct Pulmon Dis. 2018; 13: 2569-75.
  21. Breyer MK, Spruit MA, Celis AP, Rutten EP, Janssen PP, Wouters EF. Highly elevated C-reactive protein levels in obese patients with COPD: a fat chance? Clin Nutr. 2009; 28(6): 642-7.
  22. Pahlavani M, Ramalho T, Koboziev I, LeMieux MJ, Jayarathne S, Ramalingam L, et al. Adipose tissue inflammation in insulin resistance: review of mechanisms mediating anti-inflammatory effects of omega-3 polyunsaturated fatty acids. J Investig Med. 2017; 65(7): 1021-7.
  23. Tkacova R. Systemic Inflammation in chronic obstructive pulmonary disease: May adipose tissue play a role? Review of the literature and future perspectives. Hindawi Publishing Corporation. Mediators Inflamm. 2010; Apr 20.
  24. Leivo-Korpela S. Adipokines in Inflammatory Lung Diseases [academic dissertation]. Tampere: University of Tampere, School of Medicine Tampere University Hospital Finland; 2014. 121 p.
  25. Zhuravleva LV, Rogacheva TA. Ozhirenie kak multidistsiplinarnaya problema-klinika, diagnostika, lechenie. Skhidnoyevropeyskyy zhurnal vnutrishnoyi ta simeynoyi medytsyny. 2017; 2: 31-5. [Russian].
  26. Kolasa-Trela R, Miszalski-Jamka T, Grudzień G, Wypasek E, Kostkiewicz M. Adiponectin, leptin, and resistin in patients with aortic stenosis without concomitant atherosclerotic vascular disease. Pol Arch Med Wewn. 2011; 121(10): 352-60.
  27. Kumor-Kisielewska A, Kierszniewska-Stępień D, Pietras T, Kroczyńska-Bednarek J, Kurmanowska Z, Antczak A, et al. Assessment of leptin and resistin levels in patients with chronic obstructive pulmonary disease. Pol Arch Med Wewn. 2013; 123(5): 215-20.
  28. Martin SS, Qasim A, Reilly MP. Leptin resistance: a possible interface of inflammation and metabolism in obesity-related cardiovascular disease. J Am Coll Cardiol. 2008; 52: 1201-10.
  29. Bruno A, Chanez P, Chiappara G, Siena L, Giammanco S, Gjomarkaj M, et al. Does leptin play a cytokine-like role within the airways of COPD patients? Eur Respir J. 2005; 26(3): 398-405.
  30. Broekhuizen R, Wouters EF, Creutzberg EC, Weling-Scheepers CA, Schols AM. Polyunsaturated fatty acids improve exercise capacity in chronic obstructive pulmonary disease. Thorax. 2005; 60(5): 376-82.
  31. Ahmad EM, Magdy MO, Nabi AA. Leptin hormone in obese and non-obese stable and exacerbated cases of chronic obstructive pulmonary disease. Egypt J Chest Dis Tuberc. 2015; 64(3): 557-65.
  32. Vernooy JH, Drummen NE, van Suylen RJ, Cloots RH, Möller GM, Bracke KR, et al. Enhanced pulmonary leptin expression in patients with severe COPD and asymptomatic smokers. Thorax. 2009; 64(1): 26-32.
  33. Broekhuizen R, Vernooy JH, Schols AM, Dentener MA, Wouters EFM. Leptin as local inflammatory marker in COPD. Respir Med. 2005; 99(1): 70-4.
  34. Takabatake N, Nakamura H, Abe S, Hino T, Saito H, Yuki H, et al. Circulating leptin in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1999; 159(4(1)): 1215-9.
  36. Calikoglu M, Sahin G, Unlu A, Ozturk C, Tamer L, Ercan B, et al. Leptin and TNF-alpha levels in patients with chronic obstructive pulmonary disease and their relationship to nutritional parameters. Respiration. 2004; 71(1): 45-50.
  37. Pamir N, McMillen TS, Kaiyala KJ, Schwartz MW, LeBoeuf RC. Receptors for tumor necrosis factor-alpha play a protective role against obesity and alter adipose tissue macrophage status. Endocrinology. 2009; 150(9): 4124-34.
  38. Hansel NN, Gao L, Rafaels NM, Mathias RA, Neptune ER, Tankersley C, et al. Leptin receptor polymorphisms and lung function decline in COPD. Eur Respir J. 2009; 34(1): 103-10.
  39. Radchenko O, Pylypiv L, Zukow W. Lung function testing according leptin levels in patients with chronic obstructive pulmonary disease. J Education Health and Sport. 2017; 7(3): 231-8.